- Conditions
- Cardiac Transplantation
- Interventions
- Daclizumab
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 1 Month to 18 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–13
of 13
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cardiac Allograft Vasculopathy
- Interventions
- Thymoglobulin
- Drug
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 1
- States / cities
- Beverly Hills, California
- Conditions
- Primary Heart Transplant, Heart Transplantation, Heart Transplant
- Interventions
- bortezomib, plasmapheresis
- Drug · Procedure
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 14
- States / cities
- Beverly Hills, California • San Francisco, California • New Haven, Connecticut + 9 more
- Conditions
- Immune Deficiency Disorders, Severe Combined Immunodeficiency, Chronic Granulomatous Disease, X-linked Agammaglobulinemia, Wiskott-Aldrich Syndrome, Hyper-IgM, DiGeorge Syndrome, Chediak-Higashi Syndrome, Common Variable Immune Deficiency, Immune Dysregulatory Disorders, Hemophagocytic Lymphohistiocytosis, IPEX, Autoimmune Lymphoproliferative Syndrome, X-linked Lymphoproliferative Syndrome
- Interventions
- Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2026
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Heart Transplantation
- Interventions
- Thymoglobulin, Mycophenolate Mofetil, Tacrolimus, Sirolimus, Corticosteroids
- Drug
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 2
- States / cities
- Los Angeles, California
- Conditions
- DiGeorge Syndrome, Complete Typical DiGeorge Anomaly
- Interventions
- Cultured Thymus Tissue for Implantation (CTTI)
- Biological
- Lead sponsor
- Sumitomo Pharma Switzerland GmbH
- Industry
- Eligibility
- Not listed
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1991 – 2017
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Bloodloss, Surgical Procedures, Operative
- Interventions
- ecallantide, placebo
- Drug
- Lead sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 276 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Montgomery, Alabama • Aurora, Colorado + 14 more
- Conditions
- CMV Viremia, Heart Transplant Infection, Heart Transplant Failure and Rejection
- Interventions
- Letermovir, Valganciclovir
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- Common Variable Immunodeficiency (CVID), Primary Immune Regulatory Disorder, Immune Dysregulation, DiGeorge Syndrome, STAT 1 Gain of Function, STAT 3 Gain of Function, Hypomorphic RAG1 Deficiency, CD40 Ligand Deficiency, Mendelian Susceptibility to Mycobacterial Disease, GATA2 Associated Immunodeficiency, CD40 Deficiency, Hypomorphic RAG2 Deficiency, Immune Dysregulation Polyendocrinopathy Enteropathy X-Linked Syndrome, Omenn Syndrome, Chronic Granulomatous Disease
- Interventions
- Hematopoietic stem cell transplant (HSCT)
- Biological
- Lead sponsor
- Paul Szabolcs
- Other
- Eligibility
- 5 Years to 40 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Coronary Artery Stenosis, Myocardial Revascularization, Myocardial Ischemia
- Interventions
- Percutaneous Coronary Intervention, Coronary Artery Bypass Grafting
- Procedure
- Lead sponsor
- Ministry of Science and Higher Education, Poland
- Government
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2005
- U.S. locations
- 2
- States / cities
- Bryn Mawr, Pennsylvania • San Antonio, Texas
- Conditions
- Chronic Coronary Occlusion, Unprotected Left Main Coronary Artery Disease, Stent Thrombosis, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
- Interventions
- Percutaneous Coronary Intervention, CABG
- Device · Procedure
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,905 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2019
- U.S. locations
- 1
- States / cities
- Santa Clara, California
- Conditions
- Cardiovascular Disease
- Interventions
- Hemolink (hemoglobin raffimer IV solution)
- Drug
- Lead sponsor
- Hemosol
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 19
- States / cities
- San Francisco, California • Stanford, California • Sarasota, Florida + 14 more
- Conditions
- Blood Loss, Surgical
- Interventions
- Ecallantide, Placebo
- Drug
- Lead sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 8 more